Articles On Resonance Health (ASX:RHT)
Title | Source | Codes | Date |
---|---|---|---|
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | RHT | 3 weeks ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | RHT | 1 month ago |
Closing Bell: ASX ends it like Beckham… lower and with a pretty whimper, which could still suggest good things ahead
The ASX benchmark has closed slightly lower on Friday Losses across the Energy Sector weighed Small caps led ID8 The Aussie sharemarket has ended lower on Friday, driven to a small disgrace by the ongoing declines in oil prices – down... |
Stockhead | RHT | 4 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | RHT | 4 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | RHT | 5 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | RHT | 6 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | RHT | 6 months ago |
Resonance Health announces the appointment of chief financial officer
Resonance Health (ASX:RHT) has announced that Benjamin Carruthers has been appointed its chief financial officer and is expected to commence the role in October. |
BiotechDispatch | RHT | 6 months ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | RHT | 6 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | RHT | 6 months ago |
TMH Market Close: ASX200 finishes the week on a high
The ASX200 had a stronger session than expected, closing up, but only just. The real estate sector led the way gaining 1.8 per cent, utilities were also up by a per cent and materials just short of a per cent. In the green Goodman... |
themarketherald.com.au | RHT | 7 months ago |
In Case You Missed It: Resource tech snags the lead and a $1.55m BHP deal
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | RHT | 7 months ago |
TMH Spotlight: ASX edges higher, real estate leading gains
The ASX200 has gone against expectations and lifted ever so slightly by 0.1 of a per cent mid-session. Real estate led gainers – up nearly 1.5 per cent – but the heat was on communications and consumer discretionary which have both shed... |
themarketherald.com.au | RHT | 7 months ago |
ASX Health Stocks: Resonance Health jumps 22pc on global pharma contract
Resonance Health has been contracted by global pharma Sun Pharma New contract is worth $6.33m The Contract Research Organization (CRO) market is forecasted to grow rapidly Resonance Health (ASX:RHT), a company providing services to cli... |
Stockhead | RHT | 7 months ago |
Resonance Health (ASX:RHT) inks contract with major global pharma company
Resonance Health (RHT) is contracted by Sun Pharmaceutical Industries to provide services for its clinical trial in Australia RHT will provide clinical research organisation, laboratory analysis, and imaging services at various time poin... |
themarketherald.com.au | RHT | 7 months ago |
CLOSING BELL: Rock chips and Real Estate help keep the ASX fall to just 0.68pc for the day
The ASX grinds to a -0.68% close after another rough night on Wall Street. A late surge from the Real Estate sector saw it land on +1.11% for the day. Rock chip results dominated the Small Caps winners list – yep, it was that kinda day. ... |
Stockhead | RHT | 7 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | RHT | 7 months ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | RHT | 7 months ago |
ASX Health Stocks: Invex granted orphan drug designation in Europe; Resonance has a new CEO
Invex granted orphan drug designation in Europe Resonance Health has a new CEO EBR to raise $35m as it eyes market launch Invex Therapeutics (ASX:IXC) announced the granting of orphan drug designation (ODD) from the European Medicines A... |
Stockhead | RHT | 9 months ago |
ASX Today: Stocks to watch on Friday
Futures suggest the ASX will open lower to cap off the working week following a mixed session on Wall Street overnight. Meanwhile, oil prices plunged, sinking to below US$70 a barrel. On home soil, here are some ASX-listed companies w... |
themarketherald.com.au | RHT | 9 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | RHT | 9 months ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | RHT | 9 months ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | RHT | 9 months ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | RHT | 10 months ago |
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit Medicare, telehealth and mental... |
Stockhead | RHT | 10 months ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | RHT | 10 months ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | RHT | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | RHT | 1 year ago |
Closing Bell: Blocked! ACCC says no to TPG Telecom & Telstra deal
The ASX 200 rose a tidy 1.29% today with all sectors in the green ABS releases Aussie migrant data employment outcomes for the first time ACCC gives the thumbs down to Telstra and TPG’s merger plans The ASX 200 gained 1.29% today and... |
Stockhead | RHT | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | RHT | 1 year ago |
Resonance Health (ASX:RHT) contracted for two new clinical trials
Resonance Health (RHT) is contracted to provide services for two new clinical trials addressing iron-overload disordersThe company has signed contracts with two new pharmaceutical customers to provide FerriScan, Cardiac-T2, and related anal... |
themarketherald.com.au | RHT | 1 year ago |
ASX Health Stocks: Patent updates from Cynata and Proteomics; Ramsay sees good times ahead
Cynata gets Notice of Allowance from US Patent Office Proteomics secures patent in Hong Kong Ramsay Healthcare and Avita gave solid quarterly updates Cynata and Proteomics’ patents update Cynata Therapeutics (ASX:CYP) rose 8pc this mornin... |
Stockhead | RHT | 1 year ago |
Resonance Health’s (ASX:RHT) FerriScan now available on 3T MRI scanners
Resonance Health’s (RHT) flagship product, FerriScan, is now available for use on 3T MRI scanning machines FerriScan is internationally regarded by clinicians as the “gold standard” to measure liver iron concentration for patients with iro... |
themarketherald.com.au | RHT | 1 year ago |
Market highlights and 5 ASX small caps to watch on Monday
The ASX is set to open slightly lower on Monday US social media stocks tumbled on Friday, with Snap plunging by 39% Ahead this week, US Fed’s rate decision and Australia’s June quarter CPI Local shares are set to dip on Monday, with the A... |
Stockhead | RHT | 1 year ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | RHT | 1 year ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | RHT | 1 year ago |
Closing Bell: Saturday can’t come soon enough as Small Caps fight on muscle memory alone
ASX ends the week sore-arsed and red-faced Some shining glimmers of hope rise among wildly swinging small caps GUD has a ‘Guh’ moment as profit downgrade sends investors scurrying The ASX has spent this week being led by the nose into s... |
Stockhead | RHT | 1 year ago |
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | RHT | 1 year ago |
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | RHT | 1 year ago |
Resonance Health (ASX:RHT) strikes AI medical imaging devices agreement with CARPL.ai
Resonance Health (RHT) signs a platform integration and partnership agreement with CARPL.ai CARPL.ai is the world’s first testing and deployment platform for medical imaging AI that connects healthcare providers to third-party AI applicati... |
themarketherald.com.au | RHT | 1 year ago |
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | RHT | 1 year ago |
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal... |
Stockhead | RHT | 2 years ago |
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby... |
Stockhead | RHT | 2 years ago |
Closing Bell: ASX200 falls, small caps gain, petrol set to go psycho
The S&P/ASX200 is about seven points lower on Monday after a day of choppy trade, heavily impacted by some large cap hits, like Magellan (down about 10%) and an earlier whack for the big four banks after ANZ put out a profit warning. Bu... |
Stockhead | RHT | 2 years ago |
ASX Health Stocks: Resonance gets green light in US; Althea buys German cannabis company
Medical imaging software Resonance Health (ASX:RHT) has received the green light in the US for its LiverSmart medical device, making it eligible for recognition by the US government agencies and private insurers. Resonance received confirma... |
Stockhead | RHT | 2 years ago |
Resonance Health (ASX:RHT) breaks into Chinese market
Resonance Health (RHT) contracted by Chinese company Hangzhou Zede Pharma-Tech to provide services for a clinical study into a treatment for patients with blood disorders The company says the Hangzhou Zede Pharma-Tech study will use its Fe... |
themarketherald.com.au | RHT | 2 years ago |
Closing Bell: ASX microcaps selloff extends to 13%, Nasdaq set to dive again
Local markets had a breather in the form of a mid-week public holiday, but things weren’t much better once trading recommenced on Thursday. After initially jumping by more than 1%, the ASX microcap Emerging Companies index reversed course w... |
Stockhead | RHT | 2 years ago |
Resonance Health contracted to support NASH clinical trial
Resonance Health (ASX:RHT) has been contracted to provide liver-fat quantification services for Invictus Ops, a wholly-owned subsidiary of VGI Health Technology, for its clinical study of a potential new treatment for NASH. |
BiotechDispatch | RHT | 2 years ago |
ASX Health Stocks: Weed stock Cann Group gets licence from TGA for its cannabis facility
Medicinal cannabis stock Cann Group (ASX:CAN) has scored a regulatory milestone, after being granted a GMP licence to manufacture CBD therapeutic goods in its Southern facility in Victoria. The GMP (or Good Manufacturing Practice) license w... |
Stockhead | RHT | 2 years ago |
Closing Bell: ASX bounces back as US markets prepare for the inflation genie
ASX investors got back in the risk saddle on Wednesday, with steady gains across the large cap indexes and a 1.7% jump for the microcap Emerging Companies index. The catalyst appeared to be comments from US Fed Chair Jerome Powell overnight... |
Stockhead | RHT | 2 years ago |